Form 4: Royalty Pharma CEO Pablo Legorreta Reports Share Transfers and Derivative Acquisitions

CEO and Chairman of the Board of Royalty Pharma, Pablo G. Legorreta, reports the transfer of Class A Ordinary Shares and acquisition of Class E Ordinary Shares and options.

Summary

• On May 16, 2025, Pablo G. Legorreta, CEO and Chairman of the Board of Royalty Pharma, reported changes in his beneficial ownership of the company's securities.
• He received 530,348 Class A Ordinary Shares from the RP Management Equity Incentive Plan Trust for no consideration.
• He also acquired 13,356,742 Class E ordinary shares of Royalty Pharma Holdings Ltd (RPH) in connection with the Membership Interests Purchase Agreement.
• Legorreta also reported acquiring the right to buy 857,138 Class E Shares held by other employees if those shares are forfeited.
• Following these transactions, Legorreta directly owns 882,495 Class A Ordinary Shares.
• He also has indirect ownership through various entities and trusts, including Legorreta Investments LLC (460,139 shares), IRRA (123,310 shares), SEP/IRA (118,500 shares), Legorreta Children 2002 Trust (1,040,410 shares), GST-Exempt Legorreta 2012 Family Trust (901,590 shares), GST-Exempt Legorreta 2020 Family Trust (41,306 shares), Spouse (6,930 shares), Tata MC 35 Ltd. (292,190 shares), Son (10,000 shares), Daughter (10,000 shares), and Legorreta 2023 SR Trust (600,000 shares).

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating standard executive compensation and ownership adjustments. It doesn't inherently suggest positive or negative sentiment, but rather reflects ongoing management incentives.

Positives

• The acquisition of Class E shares and options suggests continued alignment of management's interests with the long-term performance of the company.
• The transfer of shares from the equity incentive plan indicates ongoing employee compensation and retention efforts.

Future Outlook

The vesting of Class E shares over a 5-year period suggests a long-term commitment from the CEO.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the US, ensuring transparency regarding insider transactions.
• Similar filings are made by executives at comparable companies like Gilead Sciences, Amgen, and AbbVie, reflecting their ownership stakes and transactions in their respective companies' securities.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding the CEO's ownership stake.
• The equity incentive plan impacts employees by providing them with company shares as part of their compensation.

Key Dates

Keywords

Royalty Pharma, Legorreta, Class A Ordinary Shares, Class E Shares, Beneficial Ownership, SEC Form 4, Share Transfer, Derivative Securities, Options, RPRX